SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED presented Phase III ESLIM-02 data for sovleplenib in wAIHA at…

HUTCHMED (China) Ltd · 6-K filed Jun 12, 2026 at 06:14 ET

At the news

BULLISHIMPACT 7/10

6-K filed Jun 12, 2026 at 06:14 ET

HUTCHMED presented Phase III ESLIM-02 data for sovleplenib in wAIHA at EHA 2026, showing a 66% durable response rate vs 15% placebo (p<0.0001) with a favorable safety profile. The NDA for wAIHA was accepted with priority review by China's NMPA in April 2026, and a resubmitted NDA for ITP also received priority review in February 2026. These regulatory milestones and strong efficacy data de-risk the pipeline for a second indication beyond ITP, though no revenue or earnings figures are disclosed.

  • Phase III ESLIM-02 met primary endpoint: durable response rate 66% sovleplenib vs 15% placebo (p<0.0001)
  • Overall response rate 70% vs 22% (p<0.0001); rescue therapy use reduced to 16% vs 54% (p=0.0001)
  • NDA for wAIHA accepted with priority review by NMPA in April 2026; Breakthrough Therapy Designation granted March 2026
  • Resubmitted NDA for ITP also granted priority review by NMPA in February 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access